| Back |
|
| For the immense strength & targeted approach to fight off infections |
| Product Name: |
| Tablets |
| Levofloxacin 250 mg, Ornidazole 500 mg / Levofloxacin 250/500/750 mg |
| A perfect answer to deal with infections |
| Broad range of action against atypical & typical microbes including anaerobes |
| As per TRUST (Tracking resistance in the United States today) 99.4% of 9499 isolates of S. Pneumoniae are susceptible to levofloxacin (1517 of which were Penicillin resistant) |
| Better efficacy than ciprofloxacin in resolving skin & soft tissue infections |
| Effective and safe in MDR TB - Low MIC 90 of 1 mcg / ml in MDR TB strains, Twice as active as ofloxacin M. Tuberculosis |
|
| Superior cure rates compared to cefuroxime, axetil, Ceftriaxone & Amoxycillin-Clavulanic acid
|
| Better than Gatifloxacin
|
|
| AECB
|
| CAP
|
| COMPLICATED UTI
|
| ACUTE MAXILLARY SINUSITIS
|
| SKIN & SOFT TISSUE INFECTIONS
|
|
Medical Jr.
| 1. Drugs 2002; 62)14): 2127-2167
|
| 2. J. med Assoc Thai 2001 Sep: 84(9): 1241-5
|
| 3. Chest 2003; 124: 1476-1481
|
| 4. Drugs 1998 sept; 56(3): 487-515
|
| 5. Drugs 2002; 62(14):2127-2167
|
| 6. Antimicrob agents chemother 1997 sep; 41(9) 1965-72
|
| 7. Int J Antimicrob agents 2002 aug; 20(2) 119-29
|
|
| |
|
 |